Hemophilia Treatment Market Research Report - Global Forecast to 2023

Hemophilia Treatment Market Research Report: By Type (Hemophilia A, Hemophilia B, Hemophilia C), By Treatment (Recombinant Coagulation Factor, Plasma-Derived Coagulation Factor, Desmopressin, Antifibrinolytic Agents), End User – Global Forecast Till 2023

ID: MRFR/Pharma/4233-CR | October 2018 | Region: Global | 158 pages

Market Snapshot


The global market for hemophilia treatment stood at USD 11,257.21 Mn in 2017 with the Americas region accounting for the largest market share.  MRFR projects that the market will exhibit an above-average CAGR of 6.10% during 2018 to 2023. Although hemophilia is a chronic condition, its effects can be greatly reduced with proper treatment and management. The condition can be defined as an inherited bleeding disorder, which causes poor blood clotting and exaggerated bleeding due to ‘clotting factor’ deficiency. Occurrence rate is higher in males than in females. Demand for treatment of Hemophilia A is relatively higher then type B and type C. Recombinant coagulation factor concentrate is the most common treatment for hemophilia. Increased prevalence of the disease has fueled the demand for various hemophilia treatment modules that are currently available.


Report Synopsis


This MRFR report offers a comprehensive assessment of the global market for hemophilia treatment. The report also includes a historical analysis and a five-year (2018-2023) market revenue forecast. As a part of analysis, all the important market indicators have been discussed in the report. It also offers an objective outlook towards key market drivers, opportunities and restraints. The report also includes a sub-market analysis based on the three major types of hemophilia (hemophilia A, hemophilia B, and hemophilia C).  Treatment types discussed in the report include plasma derived coagulation factor concentrate, recombinant coagulation factor concentrates, desmopressin, antifibrinolytic agents and gene therapy.


Report Coverage


Historical market trends, market dynamics, forecast, market value by region as well as by segmentation, country-level analysis for each market segment, key player’s market share analysis and market factor analysis which covers supply chain and Porter’s five forces analysis of the market.


Companies Covered


F.Hoffmann-La Roche Ltd, Octapharma, CSL Behring, Kedrion, Sanofi, Bayer AG, Baxter, Swedish Orphan Biovitrum AB, Grifols International S.A, Shire,  Pfizer Inc, and Novo Nordisk A/S.


Research Methodology


MRFR employs a core set of methodologies to accurately gauge the market which assists stakeholders in making informed growth decisions with fewer risks. MRFR's research framework comprises the integration of primary and secondary research disciplines to predict market trends. Primary research methods embody online surveys, telephonic interviews, test marketing which along with credible secondary data extracted from annual reports, SEC filings, financial reports, etc., form the gist of the research reference. Research development adheres to industry-specific research standards to assure factual accuracy which is followed by a multi-layer confirmation module to ensure the highest level of data purity with zero ambiguity. Top-down and bottom-up approaches are leveraged to garner pertinent market insights that aids in value generation for clients.
Hemophilia Treatment Market


Other Description



  • Market Denomination- USD Mn

  • Base Year- 2017

  • Forecast Period- From 2018 to 2023


Intended Audience


  •  Pharmaceutical Companies

  •  Medical Device Companies

  • Research and Development (R&D) Companies

  • Diagnostic Laboratories

  • Government Research Institute

  • Academic Institutes and Universities


For the scope of the research, MRFR’s report offers a comprehensive segmental analysis of the global market for hemophilia treatment


By Type



  • Hemophilia A

  • Hemophilia B

  • Hemophilia C


By Treatment Type



  • Plasma derived coagulation factor concentrate

  • Recombinant coagulation factor concentrates

  • Desmopressin

  • Antifibrinolytic agents

  • Gene Therapy


By End User



  • Hospitals & Clinics

  • Research Organizations

  • Others


By Region



  • North America

  • Europe

  • Asia Pacific

  • The Middle East & Africa (MEA)

  • Latin America



Frequently Asked Questions (FAQ) :


Global Hemophilia Treatment Market was valued at USD 11.2 billion in 2017.

The market is expected to exhibit a strong 6.1% CAGR over the forecast period from 2018 to 2023.

Growing advances in recombinant cell development are likely to be a major driver for the Hemophilia Treatment Market.

The leading type of hemophilia is hemophilia A, which held a share of 78.7% in the market in 2017.

Leading players in the Hemophilia Treatment Market include Octapharma, Sanofi, and Bayer, among others.

Hemophilia is commonly a genetic blood disorder which is inherited and affects the clotting function of the body due to a lack of a specific protein which is required for normal blood clotting. The disorder may also be developed over the course of a patient’s lifetime and is significantly rare. The global hemophilia treatment market is expected to grow at a CAGR of 6.10% during the forecast period from 2018 to 2023. Market observation has revealed that the global market valued USD 11,257.21 Mn in 2017 and is expected to appreciate to reach an approximate market value of USD 16,059.17 Mn by the end of 2023. These projections indicate steady and consistent growth of the global hemophilia treatment market.


Hemophilia has been found primarily to affect male babies and is often diagnosed at an early age. Women tend to be carriers of the disorder and can potentially pass it on to their children. Prevalence of hemophilia has been found to be high across the globe, and due to the fact that it is a lifelong condition without a cure, the demand for hemophilia treatment is high. Hemophilia also has a high risk of complications due to frequent blood loss such as damage to joints & muscles, and severe anemia among others. According to the World Federation of Hemophilia, the number of people suffering from hemophilia has been recorded at close to 17,000 in the U.S with other regions having significant figures as well. The demand for hemophilia treatment is growing significantly and as such is expected to drive the market. Moreover, biotechnology has progressed rapidly due to heavy investments in R&D and increasing government support. Recombinant products for the treatment of hemophilia has increased interest and demand which is expected to result in market growth.


The high cost of treatments is a key restraining factor due to the management of the disorder requiring lifetime treatment. Consistent lab testing and imaging tests to keep track of the disorder and its progression thus adding to the expense of treating hemophilia. However, gene therapy is being explored as a permanent solution for hemophilia. The absence of a cure at present and the various setbacks of treating hemophilia have increased the support for discovery of permanent and effective solutions. As a result, gene therapy offers the market with opportunity for growth in the coming years.


The global hemophilia treatment market is segmented on the basis of type, treatment, end-user, and region. Three broad types of hemophilia which include hemophilia A, hemophilia B, and hemophilia C are included in the segmentation of the report. Hemophilia A has the largest share of the global market which is expected to reach a market value of USD 12,697.99 by the end of 2023, and the segment is expected to witness growth at the highest CAGR of 6.23% over the assessment period.


Treatment of hemophilia is segmented into recombinant coagulation factor concentrates, gene therapy, plasma-derived coagulation factor concentrate, desmopressin, and antifibrinolytic agents. Recombinant coagulation factor concentrates have become a highly significant segment in the hemophilia treatment market and are also expected to grow at the highest CAGR of 7.01% during the forecast period.


End-users in the hemophilia treatment market have been segmented into research organizations, hospitals & clinics, and others. Hospitals and clinics accounted for the majority share of the market and valued USD 7594.66 in 2017. The hospital & clinics segment is expected to witness the fastest growth over the review period.


Regional Analysis


The Americas possesses the largest share of the global hemophilia treatment market due to the high occurrences of the disorder and the presence of a well-developed healthcare sector. Rising expenditure on healthcare and support for R&D activities is expected to keep the Americas in a leadership position. Europe accounts for the second largest market in the global hemophilia treatment market due to the similar growth pattern the regional market experiences. Moreover, government support for research of advanced medical therapies for hemophilia is also assisting in the development of the regional market.


Meanwhile, the Asia Pacific is set to witness the highest growth at a CAGR of 8.38% during the forecast period. The region has a rapidly advancing healthcare sector due to the rising disposable income in the region and the growing demand for advanced medical facilities. High healthcare expenditure and the presence of a large patient population is expected to impact the Asia Pacific hemophilia market positively.


Competitive Tracking


The global hemophilia treatment market report includes comprehensive profiling of important market players such as Shire, Pfizer Inc, Sanofi, Grifols International S.A, CSL Behring, Novo Nordisk A/S, Kedrion, Swedish Orphan Biovitrum AB, Bayer AG, Octapharma, F.Hoffmann-La Roche Ltd., and Baxter

Table of Contents:    

Chapter 1.    Report Prologue    

Chapter 2.    Market Introduction    

2.1    Definition    

2.2    Scope of the Study    

2.2.1    Research Objective    

2.2.2    Assumptions    

2.2.3    Limitations    

Chapter 3.    Research Methodology

3.1    Introduction

3.2    Primary Research    

3.3    Secondary research    

3.4    Market Size Estimation

Chapter 4.    Market Dynamics

4.1    Drivers    

4.2    Restraints

4.3    Opportunities    

4.4    Challenges

4.5    Macroeconomic Indicators

4.6    Technology Trends & Assessment            

Chapter 5.    Market Factor Analysis

5.1    Porter’s Five Forces Analysis

5.1.1    Bargaining Power of Suppliers    

5.1.2    Bargaining Power of Buyers

5.1.3    Threat of New Entrants    

5.1.4    Threat of Substitutes    

5.1.5    Intensity of Rivalry    

5.2    Value Chain Analysis

5.3    Investment Feasibility Analysis    

5.4    Pricing Analysis

Chapter 6.    Global Hemophilia Market, by Type

6.1    Introduction

6.2    Hemophilia A

6.2.1    Market Estimates & Forecast, 2017 – 2023

6.3    Hemophilia B

6.3.1    Market Estimates & Forecast, 2017 – 2023

6.4    Hemophilia C

6.4.1    Market Estimates & Forecast, 2017 – 2023

6.5    Others

6.5.1    Market Estimates & Forecast, 2017 – 2023

Chapter 8.    Global Hemophilia Market, by treatment

8.1    Introduction

8.2    Recombinant coagulation factor concentrates

8.2.1    Market Estimates & Forecast, 2017 – 2023

8.3    Plasma-derived coagulation factor concentrates

8.3.1    Market Estimates & Forecast, 2017 – 2023

8.4    Desmopressin

8.4.1    Market Estimates & Forecast, 2017 – 2023

8.5    Antifibrinolytic Agents

8.5.1    Market Estimates & Forecast, 2017 – 2023

Chapter 9.    Global Hemophilia Market, by End Users

9.1    Introduction

9.2    Hospitals 

9.2.1    Market Estimates & Forecast, 2017 – 2023

9.3    Clinics

9.3.1    Market Estimates & Forecast, 2017 – 2023

9.4    Diagnostic Centers

9.4.1    Market Estimates & Forecast, 2017 – 2023

9.5    Drug Stores

9.5.1    Market Estimates & Forecast, 2017 – 2023

9.6    Pharmacies

9.6.1    Market Estimates & Forecast, 2017 – 2023

9.7    Others

9.7.1    Market Estimates & Forecast, 2017 – 2023

Chapter 10.    Global Hemophilia Market, by Region

10.1    Introduction

10.2    Americas

10.2.1    North America

10.2.1.1    U.S.

10.2.1.1    Canada

10.2.2    South America

10.3    Europe

10.3.1    Western Europe

10.3.1.1    Germany

10.3.1.2    France

10.3.1.3    Italy

10.3.1.4    Spain

10.3.1.5    U.K

10.3.1.6    Rest of Western Europe

10.3.2    Eastern Europe

10.4    Asia Pacific

10.4.1    Japan

10.4.2    China

10.4.3    India

10.4.4    Australia

10.4.5    Republic of Korea

10.4.6    Rest of Asia Pacific

10.5    The Middle East & Africa

10.5.1    United Arab Emirates

10.5.2     Saudi Arabia

10.5.3    Oman

10.5.4    Kuwait

10.5.5    Qatar

10.5.6    Rest of the Middle East & Africa

Chapter 11    Company Landscape    

11.1    Introduction    

11.2    Market Share Analysis    

11.3    Key Development & Strategies    

11.3.1    Key Developments    

Chapter 12    Company Profiles    

12.1    Baxter International, Inc. 

12.1.1    Company Overview    

12.1.2    Types Overview    

12.1.3    Financials    

12.1.4    SWOT Analysis    

12.2    Bayer AG    

12.2.1    Company Overview    

12.2.2    Types Overview    

12.2.3    Financial Overview    

12.2.4    Key Developments    

12.2.5    SWOT Analysis    

12.3    Biogen

12.3.1    Company Overview    

12.3.2    Types Overview    

12.3.3    Financial Overview

12.3.4    Key Development    

12.3.5    SWOT Analysis    

12.4    CSL Ltd.

12.4.1    Company Overview    

12.4.2    Types/Business Segment Overview    

12.4.3    Financial Overview    

12.4.4    Key Development    

12.4.5    SWOT Analysis    

12.5    GENENTECH

12.5.1    Company Overview    

12.5.2    Types Overview    

12.5.3    Financial overview    

12.5.4    Key Developments    

12.6    GENENTECH Private Limited    

12.6.1    Company Overview    

12.6.2    Types Overview    

12.6.3    Financial Overview    

12.6.4    Key Developments    

12.7    NOVO NORDISK

12.7.1    Overview    

12.7.2    Types Overview    

12.7.3    Financials    

12.7.4    Key Developments    

12.7.5    SWOT Analysis    

        12.8    Others

Chapter 13    MRFR Conclusion    

13.1    Key Findings    

13.1.1    From CEO’s View Point    

13.1.2    Unmet Needs of the Market    

13.2    Key Companies to Watch    

13.3    Prediction of Hemophilia industry

Chapter 14    Appendix

LIST OF TABLES

Table 1        Hemophilia Industry Synopsis, 2017 – 2023

Table 2        Hemophilia Market Estimates and Forecast, 2017 – 2023, (USD Million)

Table 3        Hemophilia Market by Region, 2017 – 2023, (USD Million)

Table 4        Hemophilia Market by Type, 2017 – 2023, (USD Million)

Table 5        Hemophilia Market by Treatment, 2017 – 2023, (USD Million)

Table 6        Hemophilia Market by End User, 2017 – 2023, (USD Million)

Table 7        North America Hemophilia Market by Type, 2017 – 2023, (USD Million)

Table 8     North America Hemophilia Market by Treatment, 2017 – 2023, (USD Million)

Table 9     North America Hemophilia Market by End User, 2017 – 2023, (USD Million)

Table 10    US Hemophilia Market by Type, 2017 – 2023, (USD Million)

Table 11    US Hemophilia Market by Treatment, 2017 – 2023, (USD Million)

Table 12    US Hemophilia Market by End User, 2017 – 2023, (USD Million)

Table 13    Canada Hemophilia Market by Type, 2017 – 2023, (USD Million)

Table 14    Canada Hemophilia Market by Treatment, 2017 – 2023, (USD Million)

Table 15    Canada Hemophilia market by End User, 2017 – 2023, (USD Million)

Table 16    South America Hemophilia Market by Type, 2017 – 2023, (USD Million)

Table 17    South America Hemophilia Market by Treatment, 2017 – 2023, (USD Million)

Table 18    South America Hemophilia Market by End User, 2017 – 2023, (USD Million)

Table 19    Europe Hemophilia Market by Type, 2017 – 2023, (USD Million)

Table 20    Europe Hemophilia Market by Treatment, 2017 – 2023, (USD Million)

Table 21    Europe Hemophilia Market by End User, 2017 – 2023, (USD Million)

Table 22    Western Europe Hemophilia Market by Type, 2017 – 2023, (USD Million)

Table 23    Western Europe Hemophilia Market by Treatment, 2017 – 2023, (USD Million)

Table 24    Western Europe Hemophilia Market by End User, 2017 – 2023, (USD Million)

Table 25    Eastern Europe Hemophilia Market by Type, 2017 – 2023, (USD Million)

Table 26    Eastern Europe Hemophilia Market by Treatment, 2017 – 2023, (USD Million)

Table 27    Eastern Europe Hemophilia Market by End User, 2017 – 2023, (USD Million)

Table 28    Asia Pacific Hemophilia Market by Type, 2017 – 2023, (USD Million)

Table 29    Asia Pacific Hemophilia Market by Treatment, 2017 – 2023, (USD Million)

Table 30    Asia Pacific Hemophilia market by End User, 2017 – 2023, (USD Million)

Table 31    The Middle East & Africa Hemophilia Market by Type, 2017 – 2023, (USD Million)

Table 32    The Middle East & Africa Hemophilia Market by Treatment, 2017 – 2023, (USD Million)

Table 33    The Middle East & Africa Hemophilia market by End User, 2017 – 2023, (USD Million)

LIST OF FIGURES

Figure 1    Research Process

Figure 2    Segmentation for Hemophilia Market

Figure 3    Segmentation Market Dynamics for Hemophilia Market

Figure 4    Global Hemophilia market Share, by Type 2016

Figure 5    Global Hemophilia market Share, by Treatment 2016

Figure 6    Global Hemophilia market Share, by End User, 2016

Figure 7    Global Hemophilia market Share, by Region, 2016

Figure 8    North America Hemophilia market Share, by Country, 2016

Figure 9    Europe Hemophilia market Share, by Country, 2016

Figure 10    Asia Pacific Hemophilia market Share, by Country, 2016

Figure 11    Middle East & Africa Hemophilia market Share, by Country, 2016

Figure 12    Global Hemophilia market: Company Share Analysis, 2016 (%)

Figure 13    Baxter International, Inc.: Key Financials

Figure 14    Baxter International, Inc.  Segmental Revenue

Figure 15    Baxter International, Inc. : Geographical Revenue

Figure 16    Bayer AG: Key Financials

Figure 17    Bayer AG: Segmental Revenue

Figure 18    Bayer AG: Geographical Revenue

Figure 19    Biogen: Key Financials

Figure 20    Biogen: Segmental Revenue

Figure 21    Biogen: Geographical Revenue

Figure 22    CSL Ltd.: Key Financials

Figure 23    CSL Ltd.: Segmental Revenue

Figure 24    CSL Ltd.: Geographical Revenue

Figure 25    GENENTECH: Key Financials

Figure 26    GENENTECH: Segmental Revenue

Figure 27    GENENTECH Geographical Revenue

Figure 28    GENENTECH Private Limited: Key Financials

Figure 29    GENENTECH Private Limited: Segmental Revenue

Figure 30    GENENTECH Private Limited: Geographical Revenue

Figure 31    NOVO NORDISK: Key Financials

Figure 32    NOVO NORDISK: Segmental Revenue

Figure 33    NOVO NORDISK: Geographical Revenue